Research Analysts Offer Predictions for Compugen Q1 Earnings

Compugen Ltd. (NASDAQ:CGEN) – HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Compugen in a research report issued on Tuesday, May 19th. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will post earnings of ($0.10) per share for the quarter. The consensus estimate for Compugen’s current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Compugen’s Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.11) EPS, FY2028 earnings at ($0.44) EPS, FY2029 earnings at ($0.45) EPS and FY2030 earnings at ($0.30) EPS.

Other equities research analysts have also issued reports about the stock. Lake Street Capital started coverage on shares of Compugen in a report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research report on Monday, April 20th. Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, Truist Financial upgraded shares of Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Compugen Price Performance

Shares of CGEN opened at $2.73 on Wednesday. Compugen has a 1 year low of $1.29 and a 1 year high of $3.23. The stock has a 50 day simple moving average of $2.52 and a two-hundred day simple moving average of $2.00. The firm has a market cap of $258.50 million, a P/E ratio of 7.39 and a beta of 2.79.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $2.18 million for the quarter, compared to analysts’ expectations of $1.57 million. Compugen had a net margin of 47.97% and a return on equity of 53.13%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CGEN. Jane Street Group LLC increased its stake in shares of Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after buying an additional 359,785 shares during the period. Renaissance Technologies LLC boosted its position in Compugen by 12.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after buying an additional 176,088 shares during the period. XTX Topco Ltd bought a new stake in Compugen in the 4th quarter worth $104,000. Marshall Wace LLP grew its holdings in Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 61,202 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new position in shares of Compugen in the fourth quarter valued at about $84,000. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.